Phase I
The FDA issued the partial clinical hold order in response to the IND application Yumanity submitted in December last year. The company expects additional data on the directive within the next 30 days.
The problem Kinaset is trying to solve is that over time, patients receiving asthma therapies – typically inhaled corticosteroids plus bronchodilators – become steroid-refractory.
The Danish pharma giant is partnering with EraCal Therapeutics, to develop new obesity-related drug targets.
Unlike antibody-drug conjugates (ADCs) that focus on antigens, PDCs are able to target the tumor microenvironment that has universal features across solid tumors.
To alleviate the problem of antibiotic-resistant bacteria, or superbugs, several biotechnology companies are developing different strategies to target and kill these microorganisms.
Emergent BioSolutions, Vir Biotechnology and Thermo Fisher, come into 2022 with reports of new opportunities, new vaccines, and partnership expansions.
Affini-T Therapeutics unveiled its mission to target oncogenic driver mutations to deliver transformative therapies intended to cure patients.
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look.
BridgeBio Pharma had inked a non-exclusive clinical partnership with Amgen to study a combination of its BBP-398 with Amgen’s Lumakras in advanced solid tumors with the KRAS G12C mutation.
Denali Therapeutics announced that the FDA had placed a clinical hold on the IND application for DNL919 and would receive an official clinical hold letter from the agency in about 30 days.
PRESS RELEASES